Prevalence, Risk Factors and Vaccine Response against Hepatitis B in People Aged 50 Years or Older

Universal immunization against hepatitis B has contributed to reducing incidence of the disease, but older individuals remain susceptible to acquiring the hepatitis B virus worldwide. Thus, this study aimed to investigate the epidemiology of HBV infection in individuals aged 50 years and over in central Brazil and to evaluate the immunogenicity of the monovalent vaccine against hepatitis B in this age group using two vaccine regimens. Method: Initially, a cross-sectional and analytical study was carried out to investigate the epidemiology of hepatitis B. Then, individuals without proof of vaccination for hepatitis B were recruited for a phase IV randomized and controlled clinical trial using two vaccine regimens: Intervention Regimen (IR) (three doses of 40 mu g at months 0, 1 and 6) vs. Comparison Regimen (CR) (three doses of 20 mu g at months 0, 1 and 6). Results: The overall prevalence of exposure to HBV was 16.6% (95% CI: 14.0%-9.5%). In the clinical trial, statistical differences in protective titers were observed (p = 0.007; IR 96% vs. CR 86%) and the geometric mean of anti-HBs titers was higher in individuals who received the IR (518.2 mIU/mL vs. 260.2 mIU/mL). In addition, the proportion of high responders was higher among those who received the IR (65.3%). Conclusion: reinforced doses should be used in individuals aged 50 years or older to overcome the lower efficacy of the vaccine against hepatitis B.

Automated summary

Universal immunization has reduced the incidence of hepatitis B, but older individuals are still susceptible. This study investigated the epidemiology of HBV infection in individuals aged 50 years and over in central Brazil and evaluated the immunogenicity of the monovalent vaccine against hepatitis B in this age group. The study concludes that reinforced doses should be used to improve the efficacy of the vaccine in individuals aged 50 years or older.